Compliance and tolerability of mefloquine and chloroquine plus proguanil for long-term malaria chemoprophylaxis in groups at particular risk (the military)

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 93, Issue 1, 1999, Pages 73-77

  Peragallo, Mario S ^a,d   Sabatinelli, Guido ^b   Sarnicola, Giuseppe ^c  

^a Ospedale Militare   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c Ispettorato Logistico dell'Esercito   (Italy)

^d Ctro Studi Ric San Vet Militare   (Italy)

Author keywords

Chemoprophylaxis; Chloroquine; Compliance; Malaria; Mefloquine; Mozambique; Proguanil; Side effects; Somalia; Tolerability

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; MEFLOQUINE; PROGUANIL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; MENTAL DISEASE; MOZAMBIQUE; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; RISK; SOLDIER; SOMALIA;

PLASMODIUM FALCIPARUM; PROTOZOA; SOMALIA;

EID: 0033043667     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(99)90187-6     Document Type: Article

References (11)

1. Barrett, P. J., Emmins, P. D., Clarke, P. D. & Bradley, D. J. (1996). Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. British Medical Journal, 313, 525-528.
2. Croft, A. M. J., Clayton, T. C. & World M. J. (1997). Side effects of mefloquine prophylaxis of malaria: an independent randomized controlled trial. Transactions of the Royal Society of Tropical Medicine and Hygiene, 91, 199-203.
3. Hopperus Buma, A. P. C. C., Van Thiel, P. P. A. M., Lobel, H. O., Ohrt, C., van Ameijden, E. J. C., Veltink, R. L., Tendeloo, D. C. H., van Gool, T., Green, M. D., Todd, G. D., Kyle, D. E. & Kager, P. A. (1996). Long-term malaria chemoprophylaxis with mefloquine in Dutch Marines in Cambodia. Journal of Infectious Diseases, 173, 1506-1509.
4. Lobel, H. O., Miani, M., Eng, T., Bernard, K. W., Hightower, A. W. & Campbell, C. C. (1993). Long-term malaria prophylaxis with weekly mefloquine. Lancet, 341, 841-851.
5. Mausner, J. S. & Bahn, A. K. (1974). Methods for the study of chronic disease. In: Epidemiology. An Introductory Text, 1st edition. Philadelphia: W. B. Saunders, pp. 325-327.
6. Phillips-Howard, P. & ter Kuile, F. O. (1995). CNS adverse events associated with antimalarial agents. Drug Safety, 12, 370-383.
7. Steffen, R., Heusser, R., Mächler, R., Bruppacher, R., Naef, U., Chen, D., Hofmann, A. M. & Somaini, B. (1990). Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions and efficacy. Bulletin of the World Health Organization, 68, 313-322.
8. Steffen, R., Fuchs, E., Schildknecht, J., Naef, U., Funk, M., Schlagenhauf, P., Phillips-Howard, P., Nevill, C. & Stürchler, D. (1993). Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet, 341, 1299-1303.
9. White, N. J. (1994). Mefloquine. British Medical Journal, 308, 286-287.
10. WHO [Malaria Unit] (1991). Review of the central nervous system adverse events related to the antimalarial, mefloquine (1985-1990). Geneva: World Health Organization, mimeographed document WHO/MAL91.1063.
11. WHO (1997). Malaria. In: International Travel and Health:Vaccination Requirements and Travel Advice. Situation as on 1 January 1997 (Italian edn). Geneva:World Health Organization, pp. 70-85.